Max Robotics — Global Service Robot Directory + US Certification

About

Xiangquan Qin is a leading surgeon-scientist advancing the field of thyroid cancer surgery through rigorous comparative effectiveness research. His work focuses on evaluating the safety, efficacy, and patient-centered outcomes of robotic thyroidectomy (RT) versus traditional open thyroidectomy (OT). Qin’s major contributions include pioneering the "super-meticulous capsular dissection" (SMCD) technique, which aims to minimize complications while preserving oncologic integrity. His 2023 prospective cohort study (19 citations) provided critical evidence that robotic surgery can achieve comparable parathyroid function preservation and quality of life outcomes to open surgery. Building on this, his 2024 observational cohort study (5 citations) introduced a novel dynamic risk assessment system incorporating radioactive iodine (RAI) efficacy evaluation, offering a more personalized approach to postoperative management. By systematically comparing surgical approaches and integrating functional outcomes with dynamic risk stratification, Qin is helping to define best practices for thyroid cancer care. His work directly addresses the critical balance between surgical innovation and patient safety, making him an influential voice in endocrine surgery and a key contributor to evidence-based guidelines for minimally invasive thyroid procedures.